Some of the classical disease-modifying therapies (DMTs) for MS, such as Interferon-β, Fingolimod, and Glatiramer, have an effect in increasing anti-inflammatory cytokines especially IL-10 (34, 35). This evidence concerns the gene PPIB and myeloid sarcoma.